Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

of lower loss from operations and higher common shares outstanding due to a public offering of shares of the Company's common stock in the first quarter of 2013, pursuant to which the Company raised net proceeds of approximately $42.7 million through the issuance of 69,696,970 shares of common stock.

As of March 31, 2013, the Company had cash, cash equivalents and short-term investments of $54.4 million, as compared to $24.8 million at December 31, 2012.  The increase in cash was primarily attributable of a public offering of shares of the Company's common stock in first quarter of 2013.  On April 5, 2013, the Company refinanced its long-term debt.  The new long-term debt has a principal amount of $20 million which amortizes at an average monthly cost of approximately $289,000 through October 2016, as compared to approximately $950,000 in monthly debt cost prior to the refinance.

On May 16, 2013 at 11:00 a.m. PDT, Anthera Pharmaceuticals, Inc. will hold its annual shareholder meeting at 1204 Burlingame Avenue #8, Burlingame, CA  94010.  Prior to the meeting the Company encourages all shareholders to cast their votes on proposals presented in the proxy materials. Our Shareholder Letter, Annual Report for the fiscal year ended December 31, 2012, as well as our Proxy Statement for the annual shareholder meeting scheduled for May 16, 2013, are available free of charge on our website at www.anthera.com. Interested parties can request a copy free of charge by calling Investor Relations at 510-856-5600 or sending an e-mail request to Investor Relations by accessing our website (www.anthera.com), selecting the "Investors" tab and then selecting "Investor Contact." Please include your contact information with the request.

Following the annual shareholder meeting, the Company will host a conference call on May 20, 2013 at 2:
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... and CAMBRIDGE, Mass., May 28, 2015  Shareholder rights ... whether certain officers and directors of Eleven ... shareholders.  Eleven Biotherapeutics is a clinical-stage biopharmaceutical company ... protein therapeutics to treat eye diseases, primarily in ... View this press release on the ...
(Date:5/28/2015)... , May 27, 2015 The amount Americans ... in 2014 and with growth of 8% will reach ... out of pocket: directly on expenditures, co-pays as part ... and on premiums.  The publisher made its finding in ... the United States . ...
(Date:5/28/2015)... , May 28, 2015 ... Testing Market - Size, Industry Analysis, Trends, Opportunities, Growth and ... reach $3.6 billion by 2020. The secondary syphilis testing ... 2020. Latin America , ... (LAMEA) market accounted for about 43% revenue share ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3
... Global Sources (Nasdaq: GSOL ) has ... China Sourcing Fairs at Hong ... the renewed contracts announced in June 2010, representing a ... (Logo: http://photos.prnewswire.com/prnh/20030303/LNM011LOGO-b) Under the terms of the ...
... (Nasdaq: AMGN ) today announced the publication ... 1,776 advanced cancer patients with different types of solid ... myeloma, which compared XGEVA ™ (denosumab) to Zometa® ... which appeared today in the Journal of Clinical ...
Cached Medicine Technology:Global Sources extends its contract with AsiaWorld-Expo to host China Sourcing Fairs in Hong Kong through 2014 2Global Sources extends its contract with AsiaWorld-Expo to host China Sourcing Fairs in Hong Kong through 2014 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8
(Date:5/28/2015)... Restricting access to firearms for people ... that more clearly define alcohol misuse should be developed ... research and public policies by the UC Davis Violence ... 30 in the peer-reviewed journal Preventive Medicine , ... alcohol misuse in association with firearm access and use, ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... May 28, 2015 Medelis, Inc., a ... joined the company in the role of president. , “ ... in the CRO industry,” said Larry Flanagan, Medelis’ CEO and ... company through our next phase of growth.” , Taaffe ... growth from nine employees to over 4,500 employees, achieving 12 ...
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall of ... Board of Directors members, will be hosting their 34th ... 4-7. For the past 34 years, the Havlicek’s have ... for children by bringing together friends, families, and celebrities ... Havlicek Celebrity Fishing Tournament will be held from June ...
(Date:5/28/2015)... May 28, 2015 Workers’ compensation costs per ... state, a recent study by the Workers Compensation Research ... a three-year period. , The WCRI study, CompScope™ Benchmarks ... workers missed seven days or more of work with those ... average 2011 Michigan claim was 4 percent lower than similar ...
Breaking Medicine News(10 mins):Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 3Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 4Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2
... that subconjunctivally delivered insulin ameliorates degenerative and inflammatory responses ... Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting ... on Thursday, May 10 from 10:45 a.m. to 12:30 ... County Convention Center. ,Regular human insulin in ...
... to uncover the medium- and large-scale genetic differences between humans ... wide range of diseases, according to a paper by Howard ... in the May 10, 2007, Nature. The undertaking will help ... amount to as much as five to ten percent of ...
... systems of humans and opossums, the famous Australian marsupial ... in the understanding and treatment of facial tumours afflicting ... the Australian island state of Tasmania. ... genetic information of the South American opossum, the first ...
... two-thirds of US children undergo some trauma or ... them experience post-traumatic stress disorder. ,The ... it also suggests that the way children process troubling ... Duke University Medical Center, whose study appeared in the ...
... at St. Jude Children's Research Hospital had a molecules ... as it assembled on a double-strand break to ... that cut completely across the twisted, ladder-like structure of ... a technique developed specifically for this project, the St. ...
... People infected with the hepatitis C virus (HCV) are ... of the lymphatic system), according to a study ... Journal of the American Medical Association. Researchers from the ... of Health, and Baylor College of Medicine, found that ...
Cached Medicine News:Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:DNA Repair Proteins Monitored at Double-strand Break 2Health News:Risk of Lymphoma Increases With Hepatitis C Virus Infection 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: